Expressing the sense of Congress about the Food and Drug Administration proposal to designate the use of chlorofluorocarbons in metered-dose inhalers as non-essential.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 9, 1997)
Expresses the sense of the Congress that: (1) a specified proposed Food and Drug Administration (FDA) regulation to designate the use of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs) as nonessential so as to make MDIs using CFCs adulterated devices puts at risk the health of millions of asthma patients and does not contribute measurably to protection of the environment; and (2) the FDA should withdraw its proposal and focus its efforts on implementing existing Montreal Protocol decisions that will facilitate a transition to CFC-free MDIs by 2005.
What just happenedJul 14, 1997
Referred to the Subcommittee on Health and Environment.
Who’s behind it
- Introduced in HouseJul 9, 1997
- Jul 14, 1997CommitteeH11000
Referred to the Subcommittee on Health and Environment.
Health and Environment Subcommittee - Jul 9, 1997IntroReferralH11100
Referred to the House Committee on Commerce.
Energy and Commerce Committee - Jul 9, 1997IntroReferralIntro-H
Introduced in House
- Jul 9, 1997IntroReferral1000
Introduced in House